Table 2.

Results of intervention analysis for specified antihypertensive medications overall and within specified subgroups.

VariableACEI or ARBβ-BlockersCalcium-Channel BlockersDiuretics
Pre-ESRDDialysis InitiationPost-ESRDPre-ESRDDialysis InitiationPost-ESRDPre-ESRDDialysis InitiationPost-ESRDPre-ESRDDialysis InitiationPost-ESRD
Entire cohort1.01 (1.00 to 1.03)1.04 (1.00 to 1.09)0.96 (0.94 to 0.98)1.08 (1.07 to 1.10)0.98 (0.95 to 1.00)0.89 (0.88 to 0.90)1.11 (1.09 to 1.12)0.91 (0.88 to 0.94)0.86 (0.85 to 0.88)1.10 (1.09 to 1.12)0.60 (0.57 to 0.62)0.82 (0.81 to 0.83)
Subgroups
 Black1.01 (0.98 to 1.04)1.12 (1.03 to 1.21)0.97 (0.94 to 1.00)1.09 (1.07 to 1.11)1.00 (0.96 to 1.05)0.89 (0.87 to 0.91)1.09 (1.07 to 1.12)0.94 (0.89 to 0.98)0.88 (0.86 to 0.90)1.10 (1.08 to 1.12)0.58 (0.54 to 0.63)0.81 (0.79 to 0.83)
 Nonblack1.01 (0.99 to 1.03)1.01 (0.95 to 1.07)0.95 (0.93 to 0.97)1.08 (1.06 to 1.10)0.97 (0.94 to 1.00)0.89 (0.88 to 0.90)1.11 (1.10 to 1.13)0.90 (0.86 to 0.93)0.86 (0.84 to 0.87)1.10 (1.09 to 1.12)0.60 (0.57 to 0.63)0.83 (0.81 to 0.84)
 Diabetes mellitus1.02 (1.00 to 1.03)1.05 (1.00 to 1.10)0.96 (0.94 to 0.98)1.08 (1.07 to 1.10)0.98 (0.95 to 1.01)0.89 (0.88 to 0.90)1.11 (1.09 to 1.13)0.91 (0.88 to 0.95)0.86 (0.85 to 0.88)1.10 (1.09 to 1.11)0.60 (0.57 to 0.63)0.83 (0.81 to 0.84)
 No diabetes mellitus1.01 (0.97 to 1.04)1.00 (0.90 to 1.12)0.97 (0.93 to 1.01)1.08 (1.06 to 1.11)0.96 (0.91 to 1.02)0.89 (0.86 to 0.91)1.09 (1.07 to 1.12)0.91 (0.85 to 0.97)0.87 (0.84 to 0.90)1.12 (1.09 to 1.15)0.60 (0.54 to 0.66)0.80 (0.77 to 0.83)
 Coronary heart disease1.01 (0.99 to 1.04)1.02 (0.96 to 1.08)0.96 (0.94 to 0.99)1.07 (1.05 to 1.09)0.97 (0.94 to 1.00)0.90 (0.89 to 0.92)1.09 (1.07 to 1.11)0.89 (0.85 to 0.93)0.88 (0.86 to 0.90)1.10 (1.08 to 1.11)0.58 (0.55 to 0.61)0.83 (0.82 to 0.85)
 No coronary heart disease1.01 (0.99 to 1.03)1.08 (1.01 to 1.16)0.95 (0.93 to 0.98)1.09 (1.07 to 1.11)1.00 (0.95 to 1.04)0.88 (0.86 to 0.90)1.11 (1.09 to 1.13)0.94 (0.89 to 0.98)0.86 (0.84 to 0.88)1.11 (1.09 to 1.13)0.63 (0.59 to 0.68)0.81 (0.79 to 0.83)
 Systolic heart failure1.03 (0.97 to 1.11)1.03 (0.92 to 1.16)0.94 (0.88 to 1.01)1.08 (1.03 to 1.12)0.98 (0.92 to 1.04)0.90 (0.86 to 0.93)1.10 (1.03 to 1.17)0.89 (0.81 to 0.98)0.88 (0.82 to 0.94)1.10 (1.06 to 1.14)0.56 (0.52 to 0.62)0.84 (0.80 to 0.87)
 No systolic heart failure1.01 (1.00 to 1.03)1.05 (0.99 to 1.10)0.96 (0.94 to 0.98)1.08 (1.07 to 1.10)0.98 (0.95 to 1.00)0.89 (0.88 to 0.90)1.11 (1.09 to 1.12)0.92 (0.89 to 0.96)0.86 (0.85 to 0.88)1.10 (1.09 to 1.12)0.61 (0.58 to 0.64)0.82 (0.80 to 0.83)
  • The pre-ESRD and post-ESRD values indicate relative rate of medication use per quarter relative to the prior quarter (95% confidence intervals using a Bonferroni-corrected cutoff P value of <0.001). Values for dialysis initiation indicate the relative change in level of medication use associated with dialysis initiation (95% confidence interval). ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker.